Inventor · disambiguated record
Dario Ballinari
Also filed as: BALLINARI DARIO
19 granted patents·5 pending applications·533 citations·filing 1993–2010
95Inventor score
Files withPHARMACIA & UPJOHN SPA10NERVIANO MEDICAL SCIENCES SRL4PHARMACIA SPA4ERBA CARLO SPA3BALLINARI DARIO1
Top patents by PatentIndex Score
24 records- 0193US5397787AVinylene-azaindole derivativesERBA CARLO SPA·Filed 1993·Granted Mar 14, 1995·191 cites·8 claims
- 0289US5840745AHydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitorsPHARMACIA SPA·Filed 1995·Granted Nov 24, 1998·91 cites·13 claims
- 0380US5576330ABiologically active 3-substituted oxindole derivatives useful as anti-angiogenic agentsERBA CARLO SPA·Filed 1994·Granted Nov 19, 1996·43 cites·22 claims
- 0478US5731313AUse of anthracyclinone derivatives in amyloidosisPHARMACIA & UPJOHN SPA·Filed 1995·Granted Mar 24, 1998·18 cites·10 claims
- 0576US5849710ASubstituted indolylmethylene-oxindole analogues as tyrosine kinase inhibitorsPHARMACIA & UPJOHN SPA·Filed 1996·Granted Dec 15, 1998·43 cites·12 claims
- 0674US8927530B2Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agentVALSASINA BARBARA·Filed 2010·Granted Jan 6, 2015·7 cites·19 claims
- 0771US5663346ASubstituted azaindolylidene compounds and process for their preparationPHARMACIA SPA·Filed 1995·Granted Sep 2, 1997·30 cites·10 claims
- 0870US5965563AAryl and heteroaryl purine compoundsPHARMACIA & UPJOHN SPA·Filed 1996·Granted Oct 12, 1999·27 cites·7 claims
- 0969US6096888AAnthracyclinone derivatives and their use in amyloidosisPHARMACIA & UPJOHN SPA·Filed 1999·Granted Aug 1, 2000·10 cites·6 claims
- 1065US5656654AArylidene and heteroarylidene oxindole derivatives and process for their preparationERBA CARLO SPA·Filed 1994·Granted Aug 12, 1997·9 cites·18 claims
- 1161US2010022553A1Therapeutic Combination Comprising an Aurora Kinase Inhibitor and ImatinibNERVIANO MEDICAL SCIENCES SRL·Filed 2009·Application pending·0 cites
- 1261US2011129467A1Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agentsNERVIANO MEDICAL SCIENCES SRL·Filed 2009·Application pending·0 cites
- 1360US5998615AAnthracyclinone derivativesPHARMACIA & UPJOHN SPA·Filed 1997·Granted Dec 7, 1999·13 cites·7 claims
- 1459US5719135ASubstituted 3-arylidene-7-azaoxindole compounds and process for their preparationPHARMACIA SPA·Filed 1995·Granted Feb 17, 1998·19 cites·12 claims
- 1558US2011117212A1Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agentNERVIANO MEDICAL SCIENCES SRL·Filed 2009·Application pending·0 cites
- 1652US5905149ASubstituted quinolymethylen-oxindole analogues as tyrosine kinase inhibitorsPHARMACIA & UPJOHN SPA·Filed 1997·Granted May 18, 1999·5 cites·7 claims
- 1751US6057326ABicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitorsPHARMACIA & UPJOHN SPA·Filed 1997·Granted May 2, 2000·9 cites·10 claims
- 1848US5744454AAnthracycline derivativesPHARMACIA & UPJOHN SPA·Filed 1995·Granted Apr 28, 1998·8 cites·31 claims
- 1944US7019002B2Pyridopyrimidinones derivatives as telomerase inhibitorsPHARMACIA & UPJOHN SPA·Filed 2002·Granted Mar 28, 2006·0 cites·9 claims
- 2044US5652250AN-substituted β-aryl- and β-heteroaryl-α-cyanoacrylamide derivatives and process for their preparationPHARMACIA SPA·Filed 1995·Granted Jul 29, 1997·5 cites·10 claims
- 2143US6147073ASubstituted tetralymethylen-Oxindoles analogues as tyrosine kinase inhibitorsPHARMACIA & UPJOHN SPA·Filed 1997·Granted Nov 14, 2000·5 cites·16 claims
- 2241US2010190736A1Morpholinyl anthracycline derivative combined with protein kinase inhibitorsNERVIANO MEDICAL SCIENCES SRL·Filed 2008·Application pending·0 cites
- 2335US2004132807A1Aurones as telomerase inhibitorsFiled 2002·Application pending·0 cites
- 2434US9119877B2Therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agentBALLINARI DARIO·Filed 2010·Granted Sep 1, 2015·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Dario Ballinari files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →